166 related articles for article (PubMed ID: 7538999)
1. Plasmapheresis combined with interferon: an effective therapy for multiple sclerosis.
Medenica RD; Mukerjee S; Alonso K; Lazovic G; Huschart T
J Clin Apher; 1994; 9(4):222-7. PubMed ID: 7538999
[TBL] [Abstract][Full Text] [Related]
2. Interferon inhibitor factor predicting success of plasmapheresis in patients with multiple sclerosis.
Medenica RD; Mukerjee S; Huschart T; Corbitt W
J Clin Apher; 1994; 9(4):216-21. PubMed ID: 7759466
[TBL] [Abstract][Full Text] [Related]
3. Systemic interferon therapy of multiple sclerosis: the pros.
Knobler RL
Neurology; 1988 Jul; 38(7 Suppl 2):58-61. PubMed ID: 3133575
[TBL] [Abstract][Full Text] [Related]
4. Natural killer cell activity in patients with multiple sclerosis: interferon and plasmapheresis.
Uchida A; Maida EM; Lenzhofer R; Micksche M
Immunobiology; 1982 Feb; 160(5):392-402. PubMed ID: 6175561
[TBL] [Abstract][Full Text] [Related]
5. Interferons in multiple sclerosis. A review of the evidence.
Panitch HS
Drugs; 1992 Dec; 44(6):946-62. PubMed ID: 1282865
[TBL] [Abstract][Full Text] [Related]
6. Increased levels of antiviral MxA protein in peripheral blood of patients with a chronic disease of unknown etiology.
Chieux V; Chehadeh W; Hautecoeur P; Harvey J; Wattré P; Hober D
J Med Virol; 2001 Oct; 65(2):301-8. PubMed ID: 11536237
[TBL] [Abstract][Full Text] [Related]
7. Plasmapheresis with immunosuppressive drug therapy in progressive multiple sclerosis. A pilot study.
Khatri BO; Koethe SM; McQuillen MP
Arch Neurol; 1984 Jul; 41(7):734-8. PubMed ID: 6234867
[TBL] [Abstract][Full Text] [Related]
8. Interferons and multiple sclerosis.
Clanet M; Blancher A; Calvas P; Rascol O
Biomed Pharmacother; 1989; 43(5):355-60. PubMed ID: 2477075
[TBL] [Abstract][Full Text] [Related]
9. [Therapeutic apheresis in multiple sclerosis].
Nomura K
Nihon Rinsho; 2003 Aug; 61(8):1388-95. PubMed ID: 12962028
[TBL] [Abstract][Full Text] [Related]
10. Lack of correlation between impaired interferon production and natural killer activity of lymphocytes in multiple sclerosis.
Stöger I; Tálas M; Benczúr M; Gyódi E; Petrányi GG; Pálffy G; Kotsy B
Arch Virol; 1982; 71(3):259-65. PubMed ID: 6179500
[TBL] [Abstract][Full Text] [Related]
11. Contrasting effects of alpha, beta, and gamma interferons on nonspecific suppressor function in multiple sclerosis.
Noronha A; Toscas A; Jensen MA
Ann Neurol; 1992 Jan; 31(1):103-6. PubMed ID: 1371908
[TBL] [Abstract][Full Text] [Related]
12. Interferon-beta enhances monocyte and dendritic cell expression of B7-H1 (PD-L1), a strong inhibitor of autologous T-cell activation: relevance for the immune modulatory effect in multiple sclerosis.
Schreiner B; Mitsdoerffer M; Kieseier BC; Chen L; Hartung HP; Weller M; Wiendl H
J Neuroimmunol; 2004 Oct; 155(1-2):172-82. PubMed ID: 15342209
[TBL] [Abstract][Full Text] [Related]
13. [The dynamics of immunological indicators in the treatment of patients with multiple sclerosis with prednisolone combined with plasmapheresis].
Neretin VIa; Gannushkina IV; Zhirnova IG; Sapfirova VA; Kir'iakov VA
Zh Nevropatol Psikhiatr Im S S Korsakova; 1988; 88(2):17-21. PubMed ID: 3259769
[TBL] [Abstract][Full Text] [Related]
14. Neutralising and binding anti-interferon-beta-I b (IFN-beta-I b) antibodies during IFN-beta-I b treatment of multiple sclerosis.
Kivisäkk P; Alm GV; Tian WZ; Matusevicius D; Fredrikson S; Link H
Mult Scler; 1997 Jun; 3(3):184-90. PubMed ID: 9310964
[TBL] [Abstract][Full Text] [Related]
15. Dynamics of immune cell trafficking in interferon-beta treated multiple sclerosis patients.
Hartrich L; Weinstock-Guttman B; Hall D; Badgett D; Baier M; Patrick K; Feichter J; Hong J; Ramanathan M
J Neuroimmunol; 2003 Jun; 139(1-2):84-92. PubMed ID: 12799025
[TBL] [Abstract][Full Text] [Related]
16. Chronic progressive multiple sclerosis: double-blind controlled study of plasmapheresis in patients taking immunosuppressive drugs.
Khatri BO; McQuillen MP; Harrington GJ; Schmoll D; Hoffmann RG
Neurology; 1985 Mar; 35(3):312-9. PubMed ID: 3974889
[TBL] [Abstract][Full Text] [Related]
17. Intermittent interferonemia and interferon responses in multiple sclerosis.
Hertzog PJ; Wright A; Harris G; Linnane AW; Mackay IR
Clin Immunol Immunopathol; 1991 Jan; 58(1):18-32. PubMed ID: 1701372
[TBL] [Abstract][Full Text] [Related]
18. Interferon-gamma, interleukin-4 and transforming growth factor-beta mRNA expression in multiple sclerosis and myasthenia gravis.
Link J
Acta Neurol Scand Suppl; 1994; 158():1-58. PubMed ID: 7732782
[TBL] [Abstract][Full Text] [Related]
19. Biologic effects of interferons: relevance to multiple sclerosis.
Rudick RA; Ransohoff RM
Mult Scler; 1995; 1 Suppl 1():S12-6. PubMed ID: 9345391
[TBL] [Abstract][Full Text] [Related]
20. [Plasmapheresis in multiple sclerosis].
Fuchs S; Pogglitsch H; Ladurner G; Lechner H
Wien Klin Wochenschr; 1984 Jan; 96(2):67-9. PubMed ID: 6710999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
